RecruitingPhase 2NCT07175038
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AllRock Bio, Inc.
- Intervention
- ROC-101(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (13)
- Arizona Pulmonary Specialists, Phoenix, Arizona, United States
- University of Colorado, Aurora, Colorado, United States
- Mayo Clinic of Florida, Jacksonville, Florida, United States
- The University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Ohio State University, Columbus, Ohio, United States
- Bend Memorial Clinic, Bend, Oregon, United States
- Temple University, Philadelphia, Pennsylvania, United States
- Peter Lougheed Centre, Calgary, Alberta, Canada
- CHU de BICETRE SERVICE PNEUMOLOGIE, Le Kremlin-Bicêtre, Val-de-Marne, France
- Medizinische Hochschule Hannover, Hanover, Lower Saxony, Germany
- Pauls Stradins Clinical University Hospital, Riga, Latvia
- Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07175038 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGNCT07013149The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNCT06998329PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArchUniversity of Sao Paulo General Hospital
- ENROLLING BY INVITATIONPHASE2NCT06992440Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionGustavo A Heresi, MD, MS
- RECRUITINGNANCT06968962Comparison of Sequential to Initial Combination Therapy in PAHSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNANCT07457762AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?University of Sao Paulo General Hospital
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →